Seeking Alpha

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest ...
C&EN

Recursion to buy AI rival Exscientia

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
Seeking Alpha

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Hello, and welcome, everybody, to Recursion's Q2 2025 Earnings Call. My name is Chris Gibson, and I'm the Co-Founder and CEO of Recursion. And I'm excited to share with you today some of the latest ...
GEN

Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...